The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The
https://
ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Share
The pharmaceutical industry is facing an ever increasing challenge to deliver safer and more effective medicines. Traditionally, drug discovery programs were driven solely by potency, regardless of the properties. As a result, the development of non-drug-like molecules was costly, had high risk and low success rate. To meet the challenges, the bar has been rising higher for drug candidates. They not only need to be active, but also drug-like to be advanced to clinical development. Drug-like properties, such as solubility, permeability, metabolic stability and transporter effects are of critical importance for the success of drug candidates. They affect oral bioavailability, metabolism, clearance, toxicity, as well as in vitro pharmacology. Insoluble and impermeable compounds can result in erroneous biological data and unreliable SAR in enzyme and cell-based assays. Rapid metabolism by enzymes and high efflux by transporters can lead to high clearance, short half-life, low systemic exposure and inadequate efficacy. Early property information helps teams make informed decisions and avoids wasting precious resources. Structure-property relationships are essential to guide structural modification to improve properties. High throughput ADME/TOX assays have been implemented and are being widely used to drive drug discovery projects in parallel with activity screening. Property design has become an integrated and inseparable part of the modern drug discovery paradigm. The approach has been proven to be a winning strategy.
Di L, et al.
Curr Opin Drug Discov Devel. 2005 Jul;8(4):495-504.
Curr Opin Drug Discov Devel. 2005.
PMID:
16022186
Stoner CL, et al.
J Pharm Sci. 2004 May;93(5):1131-41. doi: 10.1002/jps.20020.
J Pharm Sci. 2004.
PMID:
15067690
Kerns EH, et al.
Drug Discov Today. 2003 Apr 1;8(7):316-23. doi: 10.1016/s1359-6446(03)02649-7.
Drug Discov Today. 2003.
PMID:
12654544
Faller B, et al.
Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):823-33. doi: 10.1517/17425255.2.6.823.
Expert Opin Drug Metab Toxicol. 2006.
PMID:
17125403
MacCoss M, et al.
Science. 2004 Mar 19;303(5665):1810-3. doi: 10.1126/science.1096800.
Science. 2004.
PMID:
15031494
Varela MT, et al.
ACS Omega. 2023 Nov 9;8(46):44265-44275. doi: 10.1021/acsomega.3c06977. eCollection 2023 Nov 21.
ACS Omega. 2023.
PMID:
38027351
Free PMC article.
Tesla R, et al.
Nat Commun. 2024 Jul 20;15(1):6125. doi: 10.1038/s41467-024-50076-8.
Nat Commun. 2024.
PMID:
39033178
Free PMC article.
Ingram N, et al.
AAPS J. 2018 Nov 16;21(1):5. doi: 10.1208/s12248-018-0276-8.
AAPS J. 2018.
PMID:
30446887
Abram M, et al.
Int J Mol Sci. 2021 Dec 3;22(23):13092. doi: 10.3390/ijms222313092.
Int J Mol Sci. 2021.
PMID:
34884898
Free PMC article.
Yang H, et al.
Molecules. 2019 Mar 12;24(5):993. doi: 10.3390/molecules24050993.
Molecules. 2019.
PMID:
30870998
Free PMC article.
MedlinePlus Health Information
Research Materials
Miscellaneous
